journal
MENU ▼
Read by QxMD icon Read
search

Chemotherapy

journal
https://www.readbyqxmd.com/read/30408779/hepatitis-b-reactivation-rate-is-higher-undergoing-some-cytotoxic-chemotherapy-in-patients-with-solid-tumors-a-large-retrospective-study
#1
Mustafa Karaca, Deniz Tural, Emre Akar, İbrahim Çil, Savaş Bayrak, Gulsum Ozet, Orhan Kemal Yucel, Erhan Hocaoglu, Ahmet Ozet
OBJECTIVE: The reactivation rate of chronic hepatitis B virus infection in cancer patients and chemotherapy regimens thought to be associated with hepatitis reactivation were investigated. PATIENTS AND METHODS: In all, 3,890 cancer patients were included in this study. Mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were obtained. RESULTS: Only 354 patients had positive hepatitis serology results (HBsAg+)...
November 8, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29694973/sustained-erythroid-response-in-a-patient-with-myelofibrosis-receiving-concomitant-treatment-with-ruxolitinib-and-deferasirox
#2
Eugenio Piro, Maria Lentini, Luciano Levato, Antonio Russo, Stefano Molica
Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox...
April 25, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29672292/identification-of-risk-factors-in-high-dose-methotrexate-induced-acute-kidney-injury-in-childhood-acute-lymphoblastic-leukemia
#3
Dao-Hai Cheng, Hua Lu, Tao-Tao Liu, Xiao-Qin Zou, Hui-Mei Pang
AIMS: Although high-dose methotrexate (HDMTX) is an effective means for the treatment of acute lymphoblastic leukemia (ALL), the development of renal dysfunction remains a significant management challenge. This study aimed to identify the key factors in HDMTX-induced acute kidney injury (AKI) in childhood ALL. METHODS: We retrospectively analyzed the clinical data in 1,329 courses of HDMTX treatment in 336 Chinese ALL children at the First Affiliated Hospital of Guangxi Medical University from September 2012 to November 2016...
April 19, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29649816/in-vitro-antichlamydial-activity-of-1-2-3-5-tetrasubstituted-pyrrole-derivatives
#4
Hongzhang Ji, Changyue Wu, Min Ni, Nannan Feng, Chan Wang, Yu Zhao, Lingyan Liu, Shengju Yang, Xiaofeng Bao
BACKGROUND: Chlamydia is a group of bacterial pathogens distributed worldwide that can lead to serious reproductive and other health problems. The rise of antibiotic-resistant pathogens promotes the development of novel antichlamydial agents. The aim of this study is to assess in vitro antichlamydial activity of our previously synthesized 1,2,3,5- tetrasubstituted pyrroles. METHODS: The derivatives were screened for their antichlamydial activity against three Chlamydia strains by calculating IC50 values using concentration-response inhibition data between 1 and 32 μM...
April 12, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29621772/a-complete-pathological-response-to-pembrolizumab-following-ex-vivo-liver-resection-in-a-patient-with-colorectal-liver-metastases
#5
Maria Baimas-George, Erin Baker, Michal Kamionek, J Stuart Salmon, Amit Sastry, David Levi, Dionisios Vrochides
Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However, a pathologically complete response (PCR) to chemotherapy for colorectal liver metastases is still rare, and its significance is not fully understood. In this case report, we describe a patient who achieved PCR after neoadjuvant immunotherapy with pembrolizumab and a left hepatectomy using an ex vivo resection technique.
April 5, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29554654/radiotherapy-and-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-renal-cancer
#6
Michele Fiore, Rolando Maria D Apos Angelillo, Carlo Greco, Iacopo Fioroni, Edy Ippolito, Daniele Santini, Sara Ramella
Treatment of metastatic renal cell carcinoma (mRCC) has seen substantial progress over the last decade. A number of targeted therapies have been shown to improve clinical outcome. Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) are an effective option in treating mRCC. RCC is traditionally perceived to be a radioresistant malignancy with a limited role of radiotherapy (RT) in the management of localized disease. While RCC appears to be radioresistant using conventionally fractionated RT, preclinical data suggest increased radiosensitivity when an ablative, hypofractionated schedule is used...
March 19, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29554652/efficacy-of-a-propolis-based-syrup-faringel-in-preventing-radiation-induced-esophagitis-in-locally-advanced-lung-cancer
#7
Edy Ippolito, Barnaba Floreno, Carla Germana Rinaldi, Lucio Trodella, Federica Loretta Meroni, Aurelia Iurato, Rolando Maria D'Angelillo, Sara Ramella, Michele Fiore
AIM: To evaluate the efficacy of a propolis-based syrup, FARINGEL®, in preventing radiation-induced esophagitis in locally advanced lung cancer patients. METHODS: Patients were treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT). Every patient received FARINGEL at the beginning of CRT until the first follow-up. The data of the study group were compared with the data of a control group treated without the administration of the syrup...
March 19, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29533947/beneficial-and-detrimental-effects-of-antiretroviral-therapy-on-hiv-associated-immunosenescence
#8
Ornella Franzese, Maria Luisa Barbaccia, Enzo Bonmassar, Grazia Graziani
Since the introduction of highly active antiretroviral therapy more than 2 decades ago, HIV-related deaths have dramatically decreased and HIV infection has become a chronic disease. Due to the inability of antiretroviral drugs to eradicate the virus, treatment of HIV infection requires a systemic lifelong therapy. However, even when successfully treated, HIV patients still show increased incidence of age-associated co-morbidities compared with uninfected individuals. Virus- induced immunosenescence, a process characterized by a progressive decline of immune system function, contributes to the premature ageing observed in HIV patients...
March 13, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29428941/editorial-the-journal-chemotherapy-is-for-cardio-oncologists-too
#9
Giorgio Minotti
No abstract text is available yet for this article.
February 9, 2018: Chemotherapy
https://www.readbyqxmd.com/read/30372698/primary-cardioprotection-reduces-mortality-in-lymphoma-patients-with-increased-risk-of-anthracycline-cardiotoxicity-treated-by-r-chop-regimen
#10
Monika Długosz-Danecka, Alicja M Gruszka, Sebastian Szmit, Agnieszka Olszanecka, Tomasz Ogórka, Marcin Sobociński, Andrzej Jaroszyński, Katarzyna Krawczyk, Aleksander B Skotnicki, Wojciech Jurczak
BACKGROUND: Advances in anti-lymphoma therapy prolong overall survival, making late adverse effects, like doxorubicin-related cardiotoxicity, an even more important clinical issue. The effectiveness of cardioprotective strategies with close monitoring, angiotensin-converting enzyme inhibitors and/or β-blockers as well as liposomal doxorubicin are still unconfirmed in clinical practice. METHODS: This study evaluated the role of a primary cardioprotection strategy in preventing cardiovascular mortality and heart failure occurrence in non-Hodgkin lymphoma (NHL) patients with a high risk of anthracycline cardiotoxicity...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30372692/octadecyloxyethyl-adefovir-exhibits-potent-in-vitro-and-in-vivo-cytotoxic-activity-and-has-synergistic-effects-with-ara-c-in-acute-myeloid-leukemia
#11
Haytham Khoury, Ruijuan He, Aaron Schimmer, James R Beadle, Karl Y Hostetler, Mark D Minden
Acute myeloid leukemia (AML) continues to be a deadly disease, with only 50-70% of patients achieving complete remission and less than 30% of adults having sustained long-term remissions. In order to address these unmet medical needs, we carried out a high-throughput screen of an in-house library of on- and off-patent drugs with the OCI/AML-2 cell line. Through this screen, we discovered adefovir dipi-voxil (adefovir-DP) as being active against human AML. In addition to adefovir-DP, there are second-generation formulations of adefovir, including octadecyloxyethyl adefovir (ODE-adefovir) and hexadecyloxypropyl adefovir (HDP-adefovir), which were designed to overcome the pharmacokinetic problems of the parent compound adefovir...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30372691/long-term-molecular-remission-achieved-by-antibody-anti-cd22-and-ponatinib-in-a-patient-affected-by-ph-acute-lymphoblastic-leukemia-relapsed-after-second-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#12
Maria Cristina Pirosa, Salvatore Leotta, Alessandra Cupri, Stefania Stella, Enrica Antonia Martino, Luca Scalise, Giuseppe Sapienza, Valeria Calafiore, Elisa Mauro, Andrea Spadaro, Paolo Vigneri, Francesco Di Raimondo, Giuseppe Milone
Ph'+ acute lymphoblastic leukemia (Ph'+-ALL) is an oncohematologic disorder for which allogeneic bone marrow transplantation still offers the only chance of cure. However, relapse is the main reason for treatment failure, also after hematopoietic stem cell transplantation (HSCT). New drugs, such as third generation tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have expanded the therapeutic landscape, especially in patients who relapsed before HSCT. Very few reports, up to now, have described the use of both classes of these new agents in combination with donor lymphocyte infusions (DLI) in the setting of patients who relapsed after HSCT...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30347389/the-evaluation-of-durative-transfusion-of-endostar-combined-with-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer
#13
Xiaoqin Li, Guomin Gu, Faris Soliman, Andrew J Sanders, Xiuli Wang, Chunling Liu
BACKGROUND: The overall survival (OS) in non-small cell lung cancer (NSCLC) is poor, with median OS of advanced NSCLC with standard systemic chemotherapy being reported at 13.6 months and the 5-year survival rate at less than 15%. Therefore, the aim of this study was to evaluate Endostar combined with chemotherapy in patients with advanced NSCLC. METHODS: Data on 116 cases of pathologically confirmed stage IIIB-IV NSCLC were retrospectively collected. The control group was treated with chemotherapy combined with intravenous infusion of Endostar while the test group received durative transfusion of Endostar...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30304722/comparison-between-hyper-cvad-and-pethema-all-93-in-adult-acute-lymphoblastic-leukemia-a-single-center-study
#14
Nergiz Erkut, Osman Akidan, Derya Selim Batur, Volkan Karabacak, Mehmet Sonmez
BACKGROUND: Although cure rates in pediatric acute lymphoblastic leukemia (ALL) are quite high with combined chemotherapy regimens, complete response (CR) and long-term survival rates in adults are 80-90 and 30-40%, respectively. Currently, combined chemotherapy regimens, such as Hyper-CVAD and PETHEMA, are used in patients with adult ALL. However, there has been no study comparing the results of Hyper-CVAD and PETHEMA ALL-93. METHODS: In this retrospective single-center study, we evaluated the results of Hyper-CVAD and PETHEMA ALL-93 in 51 ALL patients treated between September 2008 and March 2017 at the Department of Hematology, Faculty of Medicine, Karadeniz Technical University...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30304718/pharmacokinetics-of-ceftolozane-tazobactam-during-prolonged-intermittent-renal-replacement-therapy
#15
Matthew Rawlins, Vesa Cheng, Edward Raby, John Dyer, Adrian Regli, Paul Ingram, Brett C McWhinney, Jacobus P J Ungerer, Jason A Roberts
BACKGROUND: Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely. OBJECTIVES: Herein, we describe the effect of PIRRT on the plasma pharmacokinetics of ceftolozane/tazobactam ad-ministered in a critically ill 55-year-old patient with a polymicrobial sternal wound osteomyelitis, including a multiresistant Pseudomonas aeruginosa...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30145590/no-therapeutic-effect-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-retreatment-despite-t790m-disappearance-case-report-of-3-cases
#16
Tatsuya Kodama, Keisuke Watanabe, Masaharu Shinkai, Takeshi Kaneko
BACKGROUND: T790M is a major cause of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance, but the clinical significance of T790M disappearance is unknown. CASE REPORT: We report 3 cases of pulmonary adenocarcinoma which did not respond to EGFR-TKI retreatment even with T790M disappearance. T790M mutations were detected in the pleural effusions after the tumors had acquired EGFR-TKI resistance. T790M mutations disappeared from cancer cells in the pleural effusion after a break from the treatment drug and cytotoxic agent administration...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30125887/nos3-895g-gt-t-and-cbr3-730g-gt-a-are-associated-with-recurrence-risk-in-non-muscle-invasive-bladder-cancer-with-intravesical-instillations-of-thp
#17
Qidong Zhou, Weihong Ding, Yingjie Weng, Guanxiong Ding, Guowei Xia, Jianfeng Xu, Ke Xu, Qiang Ding
OBJECTIVES: To analyze the correlation between pharmacogenomic biomarkers and the efficacy of pirarubicin (THP, also named 4'-O-tetrahydropyranyl-adriamycin) and to explore potential associations of individual genetic backgrounds with the clinical outcomes of non-muscle-invasive bladder cancer (NMIBC) patients. METHODS: Between July 2003 and June 2011, a total of 91 patients were treated with transurethral resection (TUR) of the bladder tumor and were histopathologically confirmed to have NMIBC...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30107372/clinical-impact-of-post-progression-survival-on-overall-survival-in-elderly-patients-with-non-small-cell-lung-cancer-harboring-sensitive-egfr-mutations-treated-with-first-line-egfr-tyrosine-kinase-inhibitors
#18
Hisao Imai, Yutaka Yamada, Tomohide Sugiyama, Hiroyuki Minemura, Kyoichi Kaira, Kenya Kanazawa, Takashi Kasai, Takayuki Kaburagi, Koichi Minato
BACKGROUND/AIMS: More than 50% of patients with lung cancer are aged > 65 years, and non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both elderly and adult patients. Subsequent therapies confound the capability to discern the effect of first-line chemotherapy on overall survival (OS). Therefore, using individual-level data, our study aimed to determine the relationships of progression-free survival (PFS) and post-progression survival (PPS) with OS after first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in elderly patients with NSCLC harboring sensitive EGFR mutations...
2018: Chemotherapy
https://www.readbyqxmd.com/read/30032143/host-directed-therapies-for-tuberculosis-futures-strategies-for-an-ancient-disease
#19
REVIEW
Ivana Palucci, Giovanni Delogu
The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis is worsening the global threat of tuberculosis (TB). There is a need and urgency for the development of new treatments for TB, for the management of drug resistant TB (MDR-TB) and for improved regimens against drug-susceptible TB, with the goal of reducing toxicity and length of therapy that will boost patience compliance. The paucity of new drugs is a major obstacle to design new regimens while host-directed therapies (HDTs) are emerging as a promising area of research and are opening new avenues to fight TB...
2018: Chemotherapy
https://www.readbyqxmd.com/read/29969754/specifications-of-computerized-provider-order-entry-and-clinical-decision-support-systems-for-cancer-patients-undergoing-chemotherapy-a-systematic-review
#20
REVIEW
Rezvan Rahimi, Alireza Kazemi, Hamid Moghaddasi, Khadijeh Arjmandi Rafsanjani, Gholamreza Bahoush
OBJECTIVE: Chemotherapy medication errors are catastrophic. The prescription phase in the chemotherapy process plays a key role in the creation of medication errors, and therefore the use of computerized physician order entry (CPOE) and clinical decision support system (CDS) systems is recommended to reduce chemotherapy medication errors. The purpose of this study was to carry out a systematic review on the specifications of the CPOE and CDS systems for chemotherapy prescription. MATERIALS AND METHODS: A systematic review on articles published in English up to September 22, 2017, using the 3 databases PubMed, Embase, and Medline was conducted...
2018: Chemotherapy
journal
journal
21905
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"